Karuna Therapeutics, Inc. (KRTX): Price and Financial Metrics

Karuna Therapeutics, Inc. (KRTX): $176.22

6.75 (+3.98%)

POWR Rating

Component Grades













Add KRTX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where KRTX ranks best; there it ranks ahead of 37.1% of US stocks.
  • KRTX's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • KRTX ranks lowest in Growth; there it ranks in the 8th percentile.

KRTX Stock Summary

  • For KRTX, its debt to operating expenses ratio is greater than that reported by only 6.3% of US equities we're observing.
  • KRTX's price/sales ratio is 549.24; that's higher than the P/S ratio of 99.18% of US stocks.
  • Revenue growth over the past 12 months for KARUNA THERAPEUTICS INC comes in at -71.22%, a number that bests only 2.51% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to KARUNA THERAPEUTICS INC, a group of peers worth examining would be RXDX, XENE, SRRK, CRNX, and AFMD.
  • KRTX's SEC filings can be seen here. And to visit KARUNA THERAPEUTICS INC's official web site, go to www.karunatx.com.

KRTX Valuation Summary

  • In comparison to the median Healthcare stock, KRTX's price/sales ratio is 32589.47% higher, now standing at 621.1.
  • Over the past 45 months, KRTX's EV/EBIT ratio has gone down 3.

Below are key valuation metrics over time for KRTX.

Stock Date P/S P/B P/E EV/EBIT
KRTX 2023-03-17 621.1 5.9 -23.9 -23.1
KRTX 2023-03-16 613.6 5.8 -23.6 -22.9
KRTX 2023-03-15 606.3 5.7 -23.3 -22.6
KRTX 2023-03-14 609.2 5.8 -23.5 -22.7
KRTX 2023-03-13 598.9 5.7 -23.1 -22.3
KRTX 2023-03-10 580.4 5.5 -22.3 -21.6

KRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KRTX has a Quality Grade of D, ranking ahead of 7.47% of graded US stocks.
  • KRTX's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows KRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0 NA -0.541
2021-06-30 0 NA -0.402
2021-03-31 0 NA -0.333
2020-12-31 0 NA -0.261
2020-09-30 0 NA -0.223
2020-06-30 0 NA -0.233

KRTX Price Target

For more insight on analysts targets of KRTX, see our KRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $158.36 Average Broker Recommendation 1.25 (Strong Buy)

KRTX Stock Price Chart Interactive Chart >

Price chart for KRTX

KRTX Price/Volume Stats

Current price $176.22 52-week high $278.25
Prev. close $169.47 52-week low $92.26
Day low $169.57 Volume 854,900
Day high $176.80 Avg. volume 378,739
50-day MA $192.01 Dividend yield N/A
200-day MA $195.52 Market Cap 6.08B

Karuna Therapeutics, Inc. (KRTX) Company Bio

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.

KRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

KRTX Latest Social Stream

Loading social stream, please wait...

View Full KRTX Social Stream

Latest KRTX News From Around the Web

Below are the latest news stories about KARUNA THERAPEUTICS INC that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Karuna Therapeutics to Present at the Stifel 2023 CNS Days

BOSTON, March 23, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that management will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 8:00 a.m. ET.

Yahoo | March 23, 2023

The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership

Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.

Yahoo | March 23, 2023

Why Shares of Karuna Therapeutics Were Up Wednesday

The clinical-stage biopharmaceutical company, which focuses on therapies affecting the central nervous system, has seen its shares rise by 52% over the past year but fall 11% so far in 2023. The healthcare company on Tuesday released the third positive trial result regarding KarXT, a therapy to treat adults with schizophrenia. The latest trial, KarXT's Phase 3 EMERGENT-3 trial, met its primary endpoint, the company said, showing an 8.4-point reduction on the Positive and Negative Syndrome Scale total score compared to a placebo.

Yahoo | March 22, 2023

Karuna Therapeutics Announces Pricing of Public Offering of Common Stock

BOSTON, March 22, 2023--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offering of 2,479,391 shares of its common stock at a public offering price of $161.33 per share. The gross proceeds to Karuna from the offering, before deducting the underwriting discounts and commissions and other est

Yahoo | March 22, 2023

Karuna's (KRTX) KarXT Meets Primary Goal in Schizophrenia Study

Data from a late-stage study shows that treatment with Karuna's (KRTX) lead candidate, KarXT, led to an early and sustained statistically significant reduction of symptoms of schizophrenia.

Yahoo | March 21, 2023

Read More 'KRTX' Stories Here

KRTX Price Returns

1-mo -7.31%
3-mo -10.43%
6-mo -22.07%
1-year 49.26%
3-year 146.98%
5-year N/A
YTD -10.32%
2022 50.00%
2021 28.95%
2020 34.84%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8001 seconds.